Iovance Biotherapeutics (IOVA) Cash from Investing Activities (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Cash from Investing Activities for 14 consecutive years, with $11.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 28.19% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $43.0 million (up 38.95% YoY), while the FY2025 annual figure was $47.5 million, up 149.26% from the prior year.
• Cash from Investing Activities climbed to $11.4 million in Q1 2026 per IOVA's latest filing, from $775000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $153.4 million in Q1 2023 and bottomed at -$156.8 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged $3.7 million across 5 years, with a median of $13.8 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 478.25% — and 2023, when it plunged 15901.52%.
• Iovance Biotherapeutics' Cash from Investing Activities stood at $461000.0 in 2022, then slumped by 15901.52% to -$72.8 million in 2023, then jumped by 132.5% to $23.7 million in 2024, then sank by 96.73% to $775000.0 in 2025, then surged by 1370.19% to $11.4 million in 2026.
• Business Quant data shows IOVA's Cash from Investing Activities at $11.4 million in Q1 2026, $775000.0 in Q4 2025, and $17.0 million in Q3 2025.